Jpmorgan Chase & CO Lyell Immunopharma, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LYEL
# of Institutions
119Shares Held
145MCall Options Held
2.6KPut Options Held
7.5K-
Mwg Management Ltd. Washington, DC20.2MShares$25 Million31.93% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$18.7 Million16.63% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$18.7 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$16.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.4MShares$16.6 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $307M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...